Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.31, while Sanofi SA trades at $43.75 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | SNY | |
|---|---|---|
52-Week High | $97.99 | $52.34 |
52-Week Low | $93.11 | $41.33 |
Market Cap | — | $104.83B |
Sector | — | Health |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.54, down 0.32% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 58.33, while bond market uncertainty persists amid Federal Reserve policy speculation. Recent dividend payments of $0.31-$0.32 reflect steady income distribution to shareholders.
The outlook remains cautious as bond ETFs face pressure from potential rate hikes and inflation concerns. Investment opportunity lies in Treasury exposure for portfolio diversification, though risks include interest rate sensitivity and macroeconomic volatility affecting bond valuations.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
